Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabinoids for Anxiety Disorders
NCT04569760Phase 3Withdrawn
- Sponsor
- McMaster University
- Start
- Apr 2021
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cannabidiol, dronabinol in generalized anxiety disorder (GAD), Social Anxiety Disorder (SAD), panic disorder, agoraphobia, sponsored by McMaster University. Planned start Apr 2021; status: withdrawn.
02
Drugs
cannabidioldronabinol
03
Conditions
generalized anxiety disorder (GAD)Social Anxiety Disorder (SAD)panic disorderagoraphobia
Beyond the preview
Go deeper on NCT04569760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04569760.